Navigation Links
Millennium Discovers Biomarkers Potentially Predictive of Response,to Velcade (Bortezomib) for Injection

re sensitive to VELCADE therapy. Additionally, these findings showed that the biomarkers did not predict sensitivity to dexamethasone therapy, indicating that the biomarkers may be specific to VELCADE.

"Millennium is recognized as a leader in personalized medicine, and this publication is a testament to the strength of our clinical innovation," said Nancy Simonian, M.D., Chief Medical Officer, Millennium. "The genomic findings add further knowledge about VELCADE efficacy in treating a broad range of multiple myeloma patients."

Millennium and its co-development partner, Johnson & Johnson Pharmaceutical Research and Development, L.L.C. (J&JPRD) is continuing genomics research on VELCADE in additional trials. Studies include a Phase III trial conducted by the Dutch and German co-operative groups, HOVON and GMMG, which is evaluating a VELCADE based combination in patients with newly diagnosed multiple myeloma. In addition, genomics research is ongoing in a Phase III trial evaluating a VELCADE based combination therapy in indolent non-Hodgkin's lymphoma.

"While the published results represent an important step forward in our genomics research, the next critical step is to conduct similar analyses with VELCADE in combination with other anti-cancer agents," said George Mulligan PhD, Associate Director, Translational Medicine, Millennium. "We are committed to improving outcomes for multiple myeloma patients and this work should bring us closer to determining optimal treatment strategies."

About VELCADE

VELCADE is being co-developed by Millennium and J&JPRD. Millennium is responsible for commercialization of VELCADE in the U.S.; Janssen-Cilag is responsible for commercialization in Europe and the rest of the world. Janssen Pharmaceutical K.K. is responsible for commercialization in Japan. For a limited period of time, Millennium and Ortho Biotech Inc. are co-promoting VELCADE in the U.S. VELCADE is approved in more than 80 count
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Research Supported by Samuel Waxman Cancer Research Foundation Discovers Mode of Action of Arsenic-Based Drugs in Destroying Cancer Cells
2. Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with Brutons Tyrosine Kinase Inhibitors
3. Survey: Migraine Patients Taking Potentially Addictive Barbiturate or Opioid Medications Not Approved by FDA as Migraine Treatments
4. ApoCells Cancer Predictive Index Helps Oncologists Select the Most Effective Targeted Drug Therapy
5. Introgen Reports Updated Phase 2 Advexin Data Correlating Improved Survival, Tumor Responses and Predictive p53 Biomarker
6. Indivumed Study Provides Sound Scientific Basis for a Predictive Drug Test- Platform
7. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
8. Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
9. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
10. Velcade (bortezomib) for Injection Survival Data in Front-Line Multiple Myeloma Patients to be Featured at 11th International Myeloma Workshop
11. Study Shows Velcade Plus Doxil Improves Survival in Previously Treated Patients With Multiple Myeloma
Post Your Comments:
(Date:4/1/2015)... 1, 2015 Trinity Biotech plc (Nasdaq: ... of diagnostic products for the point-of-care and clinical ... Limited, its wholly-owned subsidiary (the "Issuer"), intends to ... million aggregate principal amount of Exchangeable Senior Notes ... institutional buyers pursuant to Rule 144A under the ...
(Date:4/1/2015)... 1, 2015  Pittman Motors has significantly expanded ... PLG42K, PLG42S, PLG52, and PLG63 planetary gearboxes. These ... brushless DC motors and complement Pittman,s existing spur ... 35 standard motor-gearbox family combinations to the Pittman ... high torque loads with excellent efficiency and are ...
(Date:4/1/2015)... MOUNTAIN VIEW, Calif. , April 1, ... ) announces that it has signed a definitive ... device company that develops, manufactures and sells minimally ... drainage of targeted areas within the gastrointestinal tract. ... The Xlumena portfolio includes the ...
Breaking Medicine Technology:Trinity Biotech plc Announces Proposed Offering of $100 Million of Exchangeable Senior Notes due 2045 2Trinity Biotech plc Announces Proposed Offering of $100 Million of Exchangeable Senior Notes due 2045 3Trinity Biotech plc Announces Proposed Offering of $100 Million of Exchangeable Senior Notes due 2045 4Pittman Motors Expands PLG Planetary Gearbox Offering 2Boston Scientific Agrees to Acquire Xlumena 2Boston Scientific Agrees to Acquire Xlumena 3Boston Scientific Agrees to Acquire Xlumena 4Boston Scientific Agrees to Acquire Xlumena 5
... Simcere Pharmaceutical Group ("Simcere" or the "Company") (NYSE: ... specializing in the development, manufacturing, and marketing of ... that Shanghai Celgen Bio-Pharmaceutical Co., Ltd. ("Shanghai Celgen") ... interest, has received new drug registration approval for ...
... Cempra Pharmaceuticals, a developer of differentiated antibiotics, ... (IV) solithromycin demonstrates excellent tolerability and ... up to 800 mg.  Oral administration of solithromycin ... 1 studies.  The presentation will be at the ...
Cached Medicine Technology:Simcere Announces Recent Progress of Qiangke's Registration 2Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial 2Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial 3Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial 4Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial 5Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial 6Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial 7
(Date:4/1/2015)... today launches the Knowledge & Resource Center, a collection ... care transitions and positively impact health outcomes. , By ... tools or resources that align with its mission to ... the promotion of public policy, and education and focused ... Knowledge & Resource Center serves as a mechanism by ...
(Date:4/1/2015)... LINCOLN, R.I. (PRWEB) April 01, 2015 After ... potholes. Driving over these potholes can lead to costly damage, ... your vehicle. , Amica is sharing the following suggestions from ... have plenty of tread and be inflated to the manufacturer’s ... change in vehicle handling, excessive vibration and uneven tire wear ...
(Date:4/1/2015)... April 01, 2015 The Pennsylvania Court ... lawsuits ( http://www.risperdallawsuit2014.com/ ) has scheduled a meeting ... the Philadelphia Court of Common Pleas, the meeting will ... Hall. Court records indicate that the proceeding will address ... of Risperdal users who experienced gynecomastia (male breast growth) ...
(Date:4/1/2015)... (PRWEB) April 01, 2015 EAGAN, Minn. ... Minnesota and its family of companies (Blue Cross) today ... out the year with net income of $61.5 million, ... losses. The organization reported a net operating loss of ... a negative operating margin of one-tenth of one percent ...
(Date:4/1/2015)... Manistee, Michigan (PRWEB) April 01, 2015 ... visit Best Drug Rehabilitation’s blog, where the latest post ... of last month’s observation of Teen Dating Violence Awareness ... toolkit on this growing problem to help parents identify ... their romantic interest that might involve drugs or alcohol. ...
Breaking Medicine News(10 mins):Health News:National Transitions of Care Coalition Launches Knowledge & Resource Center 2Health News:National Transitions of Care Coalition Launches Knowledge & Resource Center 3Health News:Prepare for potholes with 7 tips from Amica Insurance 2Health News:Pennsylvania Court Overseeing Hundreds of Risperdal Lawsuits Schedules April Meeting 2Health News:Pennsylvania Court Overseeing Hundreds of Risperdal Lawsuits Schedules April Meeting 3Health News:Blue Cross and Blue Shield of Minnesota Reports 2014 Results 2Health News:Blue Cross and Blue Shield of Minnesota Reports 2014 Results 3Health News:Best Drug Rehabilitation Issues Toolkit for Teen Violence Related to Substance Abuse 2
... for female clinicians, including intelligent innovations that redefine the way women ... and first-of-their-kind enhancements, Medelita sets a new standard for quality, comfort, ... the U.S. alone wearing scrubs and lab coats to work. ... ...
... 12 Former Speaker of the,House and Founder of the ... hearing of the passing of Tony Snow:, "With the ... loving,father, and a very talented journalist., "Tony was at ... knowledge,of politics and government had been greatly expanded by his ...
... tumor suppressor instead , , FRIDAY, July 11 (HealthDay News) -- ... cancer cells in lab cultures was, until recently, thought to ... have found that a gene called TCF7L2 is active in ... malfunction in a gene. As a result, researchers suspected TCF7L2 ...
... President Sirleaf while part of Mercy Ships Crew , ... ... from a week-long international humanitarian mission to support Mercy Ships, his ... training camp with an additional sense of purpose knowing that he's ...
... Emageon Inc.,(Nasdaq: EMAG ), a leader in ... and imaging facilities,announced today that the Strategic Alternatives ... and Company as Lead Advisor and SunTrust,Robinson Humphrey ... evaluates all,strategic options available to the company., ...
... July 11 In a letter to the,Senate, ... policymakers to address critical shortfalls in legislation that ... With the Senate,poised to vote on a five-year, ... policymakers to "both set and correct policies based,on ...
Cached Medicine News:Health News:Medelita Introduces A Breakthrough In Healthcare Uniforms For Women 2Health News:Medelita Introduces A Breakthrough In Healthcare Uniforms For Women 3Health News:Newt Gingrich Statement on the Loss of Tony Snow 2Health News:Redskins' Draft Pick Malcolm Kelly Energized By Trip To Mercy Ship In Liberia 2Health News:Redskins' Draft Pick Malcolm Kelly Energized By Trip To Mercy Ship In Liberia 3Health News:Putting Health Before Politics: How the United States Senate Can Fix Global HIV/AIDS Funding 2Health News:Putting Health Before Politics: How the United States Senate Can Fix Global HIV/AIDS Funding 3Health News:Putting Health Before Politics: How the United States Senate Can Fix Global HIV/AIDS Funding 4Health News:Putting Health Before Politics: How the United States Senate Can Fix Global HIV/AIDS Funding 5
... monitors and controls patient temperature primarily in ... surgery, trauma, or other medical conditions. The ... provided from a patient temperature probe. Circulating ... and 42C (107.6F) to achieve a preset ...
... The Littmann Electronic Stethoscope Model 4100WS ... (ANR) technology allowing you to reduce ambient ... without eliminating critical body sounds. Three frequency ... lung, and other body sounds: Bell (20-200 ...
... The OmniMD orthopedics EMR addresses the vast ... specific EMR includes clinically-defined templates for common ... review of systems. The system also includes ... are used to capture accurate charges and ...
Intrinsic Dual Chamber ICD With MVP Mode (Managed Ventricular Pacing). MVP promotes intrinsic conduction and is clinically proven to reduce unnecessary right ventricular (RV) pacing to approximately...
Medicine Products: